Nanjing Leads Biolabs Co., Ltd. Announces First Patient Enrolled in Phase II Trial of Opamtistomig (LBL-024) for First-Line Esophageal Squamous Cell Carcinoma

Key Highlights

• First Patient Enrolled: The company has successfully enrolled the first patient in a Phase II clinical study evaluating Opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody, for the treatment of first-line esophageal squamous cell carcinoma (ESCC).
• Trial Details: The study is an open-label, multi-center Phase II trial led by Professor Shen Lin of Beijing Cancer Hospital, with participation from multiple hospitals across China. The trial aims to assess both efficacy and safety of Opamtistomig in ESCC patients.
• LBL-024 Overview: LBL-024 is a novel bispecific antibody targeting PD-L1 and 4-1BB, developed using the company’s proprietary X-body® platform. It is the first treatment targeting the 4-1BB receptor to reach registrational stage globally for extrapulmonary neuroendocrine carcinoma (EP-NEC).
• Regulatory Achievements: LBL-024 has received multiple designations, including:
  • Breakthrough Therapy Designation (BTD) from China’s NMPA for late-line advanced EP-NEC (October 2024)
  • Orphan Drug Designation from the FDA for NEC (November 2024)
  • Fast Track Designation from the FDA for EP-NEC (January 2026)
  • Orphan Drug Designation from the European Commission for EP-NEC (January 2026)
• Clinical Performance: LBL-024 has demonstrated first-in-class or best-in-class potential in Phase II or registrational trials for non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and EP-NEC. Positive clinical signals and favorable safety profiles have been observed as monotherapy and in combination with chemotherapy.
• Broad Cancer Application: Beyond EP-NEC, LBL-024 shows promise in multiple high unmet need tumor types, including SCLC, biliary tract cancer, ovarian cancer, NSCLC, ESCC, hepatocellular carcinoma, gastric cancer, triple-negative breast cancer, and melanoma.
• Market Opportunity: ESCC is the predominant subtype of esophageal cancer in China, with approximately 224,000 new cases and 187,000 deaths annually. Most cases are diagnosed at an advanced stage, resulting in a poor prognosis and a five-year survival rate of only 10-30%.

Potential Price Sensitive Information

• First-in-Class Potential: LBL-024’s advancement to Phase II for first-line ESCC, combined with its multiple regulatory designations and demonstrated clinical efficacy, positions the company as a potential leader in innovative oncology therapies. This could significantly impact the company’s valuation and market perception.
• Regulatory Milestones: The progress and approvals from major regulatory bodies (NMPA, FDA, EC) indicate a fast-track pathway for commercialization, which may be viewed favorably by investors and could drive share price appreciation.
• Broad-spectrum Activity: The positive signals across several difficult-to-treat cancers further enhance the market potential of LBL-024, which may attract investor attention and affect share value.
• Cautionary Statement: The company notes that it cannot guarantee successful development or commercialization of LBL-024, and shareholders are advised to exercise caution. This reminder is especially relevant given the high volatility and risk associated with biotech clinical trials.

Additional Details for Investors

• Innovative Mechanism: LBL-024 leverages a unique dual-target approach (PD-L1 and 4-1BB), aiming to relieve immunosuppression and enhance T-cell activation for synergistic cancer elimination. This differentiates it from conventional PD-1/L1 inhibitors.
• Clinical Signals in Multiple Cancers: Notably, LBL-024 has already shown encouraging results in NSCLC, SCLC, biliary tract cancer, and ovarian cancer, further supporting its broad-spectrum potential.
• Unmet Need in ESCC: The poor prognosis and high mortality associated with ESCC underscore the significance of LBL-024’s clinical development in this indication. Success in this trial could position Nanjing Leads Biolabs as a key player in ESCC treatment.
• Corporate Structure: The announcement was made by Dr. Kang Xiaoqiang, Chairman, Executive Director, and CEO. The board comprises a mix of executive, non-executive, and independent directors, reflecting robust governance.

Conclusion

The initiation of the Phase II trial for Opamtistomig (LBL-024) in first-line ESCC represents a significant milestone for Nanjing Leads Biolabs Co., Ltd. The combination of innovative science, regulatory achievements, and broad-spectrum clinical potential make this announcement highly relevant for investors. The progress of LBL-024, especially given its multiple designations and promising efficacy, could materially impact the company’s market value and investor confidence. However, risks remain, and the company cautions that successful development and commercialization are not guaranteed.

Disclaimer: This article is intended for informational purposes only and does not constitute investment advice. Clinical development in biotechnology carries high risks and uncertainties. Investors should exercise due care and consult their financial advisors before making investment decisions.

View LEADS BIOLABS-B Historical chart here